Mereo BioPharma Group plc

NasdaqCM:MREO Voorraadrapport

Marktkapitalisatie: US$657.4m

Mereo BioPharma Group Beheer

Beheer criteriumcontroles 4/4

Mereo BioPharma Group's CEO is Denise Scots-Knight, appointed in Jul 2015, has a tenure of 9.33 years. total yearly compensation is $2.22M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.92% of the company’s shares, worth $12.59M. The average tenure of the management team and the board of directors is 6.7 years and 3.6 years respectively.

Belangrijke informatie

Denise Scots-Knight

Algemeen directeur

US$2.2m

Totale compensatie

Percentage CEO-salaris25.5%
Dienstverband CEO9.3yrs
Eigendom CEO1.9%
Management gemiddelde ambtstermijn6.7yrs
Gemiddelde ambtstermijn bestuur3.6yrs

Recente managementupdates

Recent updates

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Nov 25
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Oct 17

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Oct 03

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

Analyse CEO-vergoeding

Hoe is Denise Scots-Knight's beloning veranderd ten opzichte van Mereo BioPharma Group's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023US$2mUS$565k

-US$29m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$2mUS$507k

-US$42m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$2mUS$539k

US$17m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$1mUS$545k

-US$224m

Sep 30 2020n/an/a

-US$198m

Jun 30 2020n/an/a

-US$177m

Mar 31 2020n/an/a

-US$111m

Dec 31 2019US$2mUS$518k

-US$46m

Sep 30 2019n/an/a

-US$41m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$957kUS$484k

-US$41m

Sep 30 2018n/an/a

-US$42m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$50m

Dec 31 2017US$907kUS$493k

-US$52m

Compensatie versus markt: Denise's total compensation ($USD2.22M) is below average for companies of similar size in the US market ($USD3.24M).

Compensatie versus inkomsten: Denise's compensation has been consistent with company performance over the past year.

CEO

Denise Scots-Knight (65 yo)

9.3yrs

Tenure

US$2,219,323

Compensatie

Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Denise Scots-Knight
Co-Founder9.3yrsUS$2.22m1.92%
$ 12.6m
Charles Sermon
Co-Founder9.5yrsUS$1.09m0.58%
$ 3.8m
Christine Fox
Chief Financial Officer3.8yrsUS$1.00m0.27%
$ 1.8m
John Richard
Co-Founder & Chief Business Officer9.8yrsgeen gegevensgeen gegevens
John Lewicki
Chief Scientific Officer4.3yrsgeen gegevens0.060%
$ 397.3k
Jackie Parkin
Senior VP & Therapeutic Headno datageen gegevensgeen gegevens
Alexandra Hughes-Wilson
Chief of Patient Access & Commercial Planning6.7yrsgeen gegevens0.033%
$ 216.0k
Suba Krishnan
Senior Vice President of Clinical Development3.9yrsgeen gegevensgeen gegevens
Bo Kara
Senior VP and Head of Pharmaceutical Development & CMCno datageen gegevensgeen gegevens

6.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: MREO's management team is seasoned and experienced (6.7 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Denise Scots-Knight
Co-Founder9.7yrsUS$2.22m1.92%
$ 12.6m
Michael Wyzga
Independent Non-Executive Chairman of The Board5.6yrsUS$156.80k0.016%
$ 107.2k
Deepika Pakianathan
Independent Non-Executive Director5.6yrsUS$113.76k0%
$ 0
Anders Ekblom
Independent Non-Executive Director9.3yrsUS$121.31k0.17%
$ 1.1m
Marc Yoskowitz
Independent Director2yrsUS$94.49k0.049%
$ 322.8k
Annalisa Lisa Jenkins
Independent Director2yrsUS$100.96k0.049%
$ 322.8k
Jeremy Bender
Independent Non Executive Director4.1yrsUS$105.08k0.0082%
$ 53.7k
Daniel Shames
Independent Director2yrsUS$97.75k0.049%
$ 322.8k
Pierre Jacquet
Independent Director3.2yrsUS$102.18k0.10%
$ 661.9k
Justin Roberts
Independent Director2yrsgeen gegevensgeen gegevens

3.6yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: MREO's board of directors are considered experienced (3.6 years average tenure).